Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...

GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results.

Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia ...

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.

Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

We recently published a list of Billionaire Steve Cohen’s Top 15 Stock Picks. In this article, we are going to take a look at ...

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients ...

New Delhi, Jan. 17, 2025 (GLOBE NEWSWIRE) -- The global pharma & biotech CRM software market was valued at US$ 7.21 billion IN 2024 and is projected to reach US$ 20.0 by 2033 at a CAGR of 15.2% during ...

We are thrilled to have John join the Nurix team as we prepare to launch our pivotal clinical program for NX-5948 in chronic lymphocytic leukemia and potentially other B-cell malignancies,” said ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...